Price$6.67-0.09 (-1.33%)
02:45 PM07:45 PM
News · 26 weeks46-89%
2025-12-142026-06-07
Mix1790d
- SEC Filings10(59%)
- Other5(29%)
- Earnings2(12%)
Latest news
25 items- SECSEC Form EFFECT filed by Profound Medical Corp.EFFECT - Profound Medical Corp. (0001628808) (Filer)
- SECProfound Medical Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRTelix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment ApproachesTelix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes. MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ:EDAP, "EDAP")) and Profound Medical Corp. (NASDAQ:PROF, TSX:PRN, "Profound")
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, is pleased to announce that the TULSA Procedure™ will be highlighted in four oral presentations at the upcoming American Urological Association's ("AUA") Annual Meeting in Washington, DC, in the session titled "Prostate Cancer: Localized: Ablative Therapy II" on May 16th from 1:00-3:00 p.m. ET. TULSA Procedure Talks at AUA2026 Ram A. Pathak, M.D., Associate Professor in the Department of Urology at Mayo Clinic in Florida, will give a presentation titled
- SECSEC Form S-3 filed by Profound Medical Corp.S-3 - Profound Medical Corp. (0001628808) (Filer)
- SECSEC Form 10-Q filed by Profound Medical Corp.10-Q - Profound Medical Corp. (0001628808) (Filer)
- SECProfound Medical Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical Reports Strong First Quarter 2026 Financial Results– Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULSA Procedure™ – TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, today reported financial results for the first quarter ended March 31, 2026. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAA
- PRWhy Medtech Giants Are Quietly Paying Up for AI DiagnosticsISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, April 29, 2026 /CNW/ -- USANewsGroup.com News Commentary – There's a quiet bidding war underway for AI diagnostics, and the price keeps climbing. The global AI in medical imaging market is on track to hit $2.20 billion in 2026, with a 34.8% growth rate baked in through 2033[1]. Q1 2026 healthcare M&A activity tells the same story: capital is rotating into AI-enabled platforms that already carry regulatory clearance, recurring revenue, and real clinical data behind them[2]. That description fits a short list of names worth knowing right now: VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Medtronic (NYSE:MDT), Danaher (NYSE:DHR
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to FollowTORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2026 financial results after market close on Thursday, May 7, 2026. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. First Quarter 2026 Results Conference Call Details: Date: Thursday, May 7, 2026 Time: 4:30 p.m. ET Live Call Dial-in Numbers: 1-800-717-1738 (North America) or 1-646-307-1865
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor ConferenceTORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 22, 2026 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre. The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "IR Calendar" in the Investors section. About Profound Medical Corp. Pr
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ MilestoneTORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure™ performed in Dallas Medical Center's state-of-the-art MRI suite. "Having performed hundreds of focal HIFU procedures for prostate cancer patients, we switched to primarily offering the TULSA Procedure because its unique MRI-guidance and thermography allow us to treat a much broader range of prostate diseases, si
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRCAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA treatment demonstrates a meaningful and statistically significant improvement over robotic RP in the preservation of erectile function together with continence at 6 months – TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced superiority on the prespecified, primar
- SECProfound Medical Corp. filed SEC Form 8-K: Leadership Update8-K - Profound Medical Corp. (0001628808) (Filer)
- SECProfound Medical Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24TORONTO, March 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that the first clinical outcomes from the Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA Procedure™ with robotic radical prostatectomy in men with localized prostate cancer are scheduled to be presented during the Late-Breaking and High-Impact session at the 41st Annual European Association of Urology ("EAU 2026") Congress in London, UK on March 13, 2026 at 9:40 a.m. EDT
- SECSEC Form 10-K filed by Profound Medical Corp.10-K - Profound Medical Corp. (0001628808) (Filer)
- SECProfound Medical Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Profound Medical Corp. (0001628808) (Filer)
- PRProfound Medical Reports Fourth Quarter and Full Year 2025 Financial ResultsTORONTO, March 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, today reported financial results for the fourth quarter and full year ended December 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Q4-2025 revenue grew 43% year-over-year and 13% sequentially quarter-over-quarter to a record $6.0 million. Profound's TULSA-PRO® qualified sales pipe
PROF FAQ
6 questionsWhat does Profound Medical Corp. do?
Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive...Where does PROF stock trade?
Profound Medical Corp. (PROF) is listed on NASDAQ.What sector and industry is PROF in?
Profound Medical Corp. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about PROF?
Profound Medical Corp. has had 7 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $1650.00 price target on 2024-07-23. Recent price targets range from $1000.00 to $2300.00.What companies are similar to PROF?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare PROF side-by-side with any of them on Quantisnow.How can I track PROF on Quantisnow?
Quantisnow aggregates Profound Medical Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PROF to receive live email and push alerts on every new disclosure.